

FIG. 1




FIG. 2




FIG 3




FIG. 4




FIG. 5




FIG. 6






FIG. 7

FIG. 8A and 8B



Starting Induction Trap vector.



FIGS. 8A and 8B

Figure 9A




Figure 9B (SEQ ID NO: 5)

CACGTGTTGACAATTAATCAATCGGCAATATATATCGGCATAGTATAATACGA
-35a -35b -10a -10b
RBS
CTCACTATAGGAGGC
T7 promoter




Figure 10

Figure 11: Schematic diagram of the experimental workflow for viral selection and drug screening. The process starts with a cell line, followed by adding virus and ligand, then positive selection drug, then negative selection drug, and finally rest and negative selection. The workflow is divided into two main sections: Positive Selection and Negative Selection. The first section (Positive Selection) involves adding virus and ligand, followed by positive selection drug, and then rest. The second section (Negative Selection) involves adding negative selection drug, followed by rest, and finally negative selection. The cell lines used are EL4 (6 x 10⁷) and NIH3T3 (5 x 10⁶). The drugs used are Phleomycin and Ganciclovir. The time points are 2 Days and 2 Days.






Figure 11

A.


Sentinel Library	Stimulus	Positive Selection	# Clones	# Clones Inducible SEAP
NIH3T3 IL-1 β (5 x 10**6)	IL-1 β	Phleomycin	22	12
EL4 TNF α (6 x 10**7)	TNF α	Phleomycin	183	31
EL4 TNF α	SDF-1	Phleomycin	18	7





Figures 12A and 12B



IL-1 β NIH3T3 Sentinel Lines



Figures 13A and 13B



Figures 14A and 14B

SDF-1 and TNF α regulated EL4 Sentinel Lines





Figure 14C

Effect of Celecoxib on IL-1 β response of NIH3T3 Sentinel Lines



Celecoxib

Figure 15

COX-2 inhibitor Celecoxib on TNF α response of EL-4 Sentinel Lines

Effect of COX-2 inhibitor Celecoxib on TNF α response of EL-4 Sentinel Lines






Figure 16




Figures 17A and 17B

A. Effect of MEK inhibitor U0126 on IL-1 β response of NIH3T3 Sentinel Lines



B. Effect of cyclosporin A on IL-1 β response of NIH3T3 Sentinel Lines



Figures 18A and 18B